RTP Mobile Logo
What Clinicians Want to Know About Toxicity Considerations Associated with BTK Inhibitors (Webinar Audio Proceedings)
Released September 2023

Featuring perspectives from Dr Nicole Lamanna and Dr William G Wierda. Published September 22, 2023. (Webinar Audio Proceedings)

CE Information and Faculty Disclosures

  • TARGET AUDIENCE
    This program is intended for medical and radiation oncologists, hematologists, hematology-oncology fellows, oncology nurses and other allied healthcare professionals involved in the treatment of cancer.

    LEARNING OBJECTIVES

    • Appreciate the frequency and severity of various therapy-related cardiologic adverse events (AEs) commonly encountered by patients undergoing treatment with BTK inhibitors for chronic lymphocytic leukemia or mantle cell lymphoma, and develop strategies to optimally address these complications.
    • Recognize the spectrum of hematologic AEs associated with BTK inhibitors, and use this knowledge to identify, manage and mitigate these side effects.
    • Recall commonly encountered nonhematologic AEs associated with BTK inhibitors, and appropriately intervene when these toxicities are suspected or diagnosed.
    • Compare and contrast the side-effect and toxicity profiles of the various FDA-approved BTK inhibitors, and recall the patient- and disease-specific factors affecting the decision to select one versus the others.
    • Evaluate findings from published research with BTK inhibitors in combination with other anticancer therapies, such as anti-CD20 antibodies and Bcl-2 inhibitors, to determine the current and potential roles of these novel regimens.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    CME credit is no longer available for this issue

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    CME credit is no longer available for this issue

    PRIVACY POLICY
    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Nicole Lamanna, MD
    Professor of Medicine, Leukemia Service
    Director of the Chronic Lymphocytic Leukemia Program
    Hematologic Malignancies Section
    Herbert Irving Comprehensive Cancer Center
    NewYork-Presbyterian/Columbia University Medical Center
    New York, New York

    Advisory Committee and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MingSight Pharmaceuticals, Octapharma, Oncternal Therapeutics.

    William G Wierda, MD, PhD
    Jane and John Justin Distinguished Chair in Leukemia Research in Honor of Dr Elihu Estey
    Section Chief, Chronic Lymphocytic Leukemia
    Center Medical Director
    Department of Leukemia, Division of Cancer Medicine
    Executive Medical Director, Inpatient Medical Services
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Accutar Biotechnology Inc, Bristol Myers Squibb, Cyclacel Pharmaceuticals Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Novartis, Oncternal Therapeutics, Pharmacyclics LLC, an AbbVie Company, Numab Therapeutics AG, Nurix Therapeutics Inc — Supported by the NIH/NCI under award number P30 CA016672 and using MDACC Cancer Center Support Grant (CCSG) shared resources; Nonrelevant Financial Relationship: National Comprehensive Cancer Network (Chair, CLL).

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    These activities are supported by an educational grant from AstraZeneca Pharmaceuticals LP.

    Release date: September 2023
    Expiration date: September 2024

Acknowledge and close

Listen to audio
(WIFI is recommended for best performance):